Susana Campos

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study
    Susana M Campos
    Dana Farber Partners Cancer Care, Dana Farber Cancer Institute, Boston, MA 02115, USA Electronic address
    Gynecol Oncol 133:537-41. 2014
  2. doi request reprint A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases
    Susana M Campos
    Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 9:39-44. 2009
  3. ncbi request reprint Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer
    Susana Campos
    Dana Farber Cancer Institute, Brigham and Women s Cancer Center, Boston, Massachusetts 02115, USA
    Oncologist 8:10-6. 2003
  4. ncbi request reprint Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia
    Susana M Campos
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Compr Canc Netw 3:807-16. 2005
  5. ncbi request reprint Aromatase inhibitors for breast cancer in postmenopausal women
    Susana M Campos
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncologist 9:126-36. 2004
  6. ncbi request reprint Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer
    Susana Campos
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:5597-604. 2005
  7. ncbi request reprint Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy
    Katharine M Esselen
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women s Hospital, Boston, MA 02215, USA
    Gynecol Oncol 127:51-4. 2012
  8. ncbi request reprint A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer
    Linda R Duska
    Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 96:198-203. 2005
  9. ncbi request reprint The impact of anemia and its treatment on patients with gynecologic malignancies
    Susana Campos
    Department of Medical Oncology, Dana Farber Cancer Center, Boston, MA 02115, USA
    Semin Oncol 29:7-12. 2002
  10. pmc Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
    Ursula A Matulonis
    Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
    J Clin Oncol 27:5601-6. 2009

Collaborators

Detail Information

Publications21

  1. ncbi request reprint A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study
    Susana M Campos
    Dana Farber Partners Cancer Care, Dana Farber Cancer Institute, Boston, MA 02115, USA Electronic address
    Gynecol Oncol 133:537-41. 2014
    ..Given the potential role of angiogenesis in the gynecological carcinomas, pazopanib, a VEGFR inhibitor, was investigated in the management of patients with recurrent carcinosarcoma of the uterus...
  2. doi request reprint A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases
    Susana M Campos
    Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 9:39-44. 2009
    ..Recent aromatase inhibitor studies have reported activity in such patients; therefore, this study formally evaluated anastrozole and exemestane in postmenopausal patients in this setting...
  3. ncbi request reprint Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer
    Susana Campos
    Dana Farber Cancer Institute, Brigham and Women s Cancer Center, Boston, Massachusetts 02115, USA
    Oncologist 8:10-6. 2003
    ....
  4. ncbi request reprint Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia
    Susana M Campos
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Compr Canc Netw 3:807-16. 2005
    ..Early hemoglobin response may therefore be considered as a desired goal of epoetin alfa therapies...
  5. ncbi request reprint Aromatase inhibitors for breast cancer in postmenopausal women
    Susana M Campos
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncologist 9:126-36. 2004
    ..These differences may be attributed to the androgenic effects of steroidal agents; clinical trials are currently under way to confirm these suspicions...
  6. ncbi request reprint Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer
    Susana Campos
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:5597-604. 2005
    ..To evaluate the antitumor activity and toxicity of two doses of CI-1033 in patients with platinum-refractory or recurrent ovarian cancer, and to determine baseline expression of epidermal growth factor receptor in tumor cells...
  7. ncbi request reprint Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy
    Katharine M Esselen
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women s Hospital, Boston, MA 02215, USA
    Gynecol Oncol 127:51-4. 2012
    ..To examine the distribution and outcomes of recurrent disease in patients with ovarian, fallopian tube and peritoneal cancers after optimal cytoreduction and adjuvant intraperitoneal (IP) chemotherapy...
  8. ncbi request reprint A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer
    Linda R Duska
    Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 96:198-203. 2005
    ..To determine the toxicity, tolerability, and feasibility of delivering combination chemotherapy with subsequent radiation therapy to women with high-risk endometrial cancer and to evaluate the long-term bowel toxicity of this regimen...
  9. ncbi request reprint The impact of anemia and its treatment on patients with gynecologic malignancies
    Susana Campos
    Department of Medical Oncology, Dana Farber Cancer Center, Boston, MA 02115, USA
    Semin Oncol 29:7-12. 2002
    ..Therefore, epoetin alfa treatment should be considered in this patient population...
  10. pmc Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
    Ursula A Matulonis
    Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
    J Clin Oncol 27:5601-6. 2009
    ..Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit...
  11. doi request reprint Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer
    Ursula A Matulonis
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Gynecol Oncol 126:41-6. 2012
    ..Test the safety and efficacy of sequentially blocking angiogenesis by adding oral cyclophosphamide to bevacizumab following cancer progression on bevacizumab in patients with recurrent ovarian cancer...
  12. ncbi request reprint Phase II trial of anastrozole in women with asymptomatic müllerian cancer
    Marcela G del Carmen
    Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 91:596-602. 2003
    ..To evaluate the efficacy and toxicity of the selective aromatase inhibitor anastrozole (Arimidex), we conducted a phase II trial in 53 women with asymptomatic recurrent/persistent müllerian cancer...
  13. ncbi request reprint Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy
    John G Gribben
    Department of Medical Oncology, Dana Farber Cancer Institute and Division of Medical Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 11:4430-6. 2005
    ..Anti-CYP1B1-specific T cells kill CYP1B1-expressing tumors, providing the rationale to examine CYP1B1 as a target for immunotherapy...
  14. pmc Ovarian squamous cell carcinoma arising from mature cystic teratoma
    Kavitha Parithivel
    Dana Farber Cancer Institute, Department of Radiology, 44 Binney Street, Boston, MA 02115, USA
    Cancer Imaging 11:67-9. 2011
    ..This is an interesting case presentation that has prior imaging that demonstrates imaging characteristics of the transformation of a mature cystic teratoma to squamous cell carcinoma...
  15. ncbi request reprint Hormonal therapy in postmenopausal women with breast cancer
    Susana M Campos
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
    Oncology 64:289-99. 2003
    ..In addition to their role in metastatic breast, trials investigating the potential of aromatase inhibitors in the early breast cancer, both in the adjuvant and neoadjuvant setting are underway...
  16. ncbi request reprint Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
    Harold J Burstein
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:2889-95. 2003
    ..We conducted a multicenter phase II study to evaluate the efficacy and safety of trastuzumab combined with vinorelbine, and to assess cardiac surveillance algorithms and tumor markers as prognostic tools...
  17. doi request reprint Anti-epidermal growth factor receptor strategies for advanced breast cancer
    Susana M Campos
    Department of Breast and Gynecology, Dana Farber Cancer Institute, Harvard University, Boston, Massachusetts, USA
    Cancer Invest 26:757-68. 2008
  18. ncbi request reprint Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
    ..The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin...
  19. ncbi request reprint Evolving treatment approaches for early breast cancer
    Susana M Campos
    Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA
    Breast Cancer Res Treat 89:S1-7. 2005
    ..In addition to chemotherapy, the use of hormonal therapy continues to evolve, with studies demonstrating the benefit of the aromatase inhibitors and serum estrogen receptor down-regulation...
  20. doi request reprint Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases
    Mariana C Castells
    Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, Boston, MA, USA
    J Allergy Clin Immunol 122:574-80. 2008
    ....
  21. ncbi request reprint Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies
    Richard T Penson
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 93:702-7. 2004
    ..Topotecan and pegylated liposomal doxorubicin (Doxil) interact with topoisomerase I and II (topo I and II), respectively, with schedule dependent, and potentially synergistic cytotoxicity...